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RESEARCH ARTICLE
Sensitivity and specificity of an electronic nose
in diagnosing pulmonary tuberculosis among
patients with suspected tuberculosis
Antonia M. I. SaktiawatiID1,2,3, Ymkje Stienstra4, Yanri W. Subronto1,3, Ning Rintiswati3,5,
Sumardi1, Jan-Willem Gerritsen6, Henny Oord6, Onno W. Akkerman2,7, Tjip S. van der
WerfID2,4*
1 Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
Mada, Yogyakarta, Indonesia, 2 University of Groningen, University Medical Center Groningen, Department
of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands, 3 Center for Tropical Medicine,
Universitas Gadjah Mada, Yogyakarta, Indonesia, 4 University of Groningen, University Medical Center
Groningen, Department of Internal Medicine—Infectious Diseases, Groningen, the Netherlands,
5 Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada,
Yogyakarta, Indonesia, 6 eNose B.V. (The eNose Company), Zutphen, The Netherlands, 7 University of




To investigate the potency of a hand-held point-of-care electronic-nose to diagnose pulmo-
nary tuberculosis (PTB) among those suspected of PTB.
Methods
Setting: Lung clinics and Dr. Sardjito Hospital, Yogyakarta, Indonesia. Participants: patients
with suspected PTB and healthy controls. Sampling: 5 minutes exhaled breath. Sputum-
smear-microscopy, culture, chest-radiography, and follow-up for 1.5–2.5 years, were used
to classify patients with suspected PTB as active PTB, probably active PTB, probably no
PTB, and no PTB. After building a breath model based on active PTB, no PTB, and healthy
controls (Calibration phase), we validated the model in all patients with suspected PTB (Vali-
dation phase). In each variable (sex, age, Body Mass Index, co-morbidities, smoking status,
consumption of alcohol, use of antibiotics, flu symptoms, stress, food and drink intake), one
stratum’s Receiver Operating Characteristic (ROC)-curve indicating sensitivity and specific-
ity of the breath test was compared with another stratum’s ROC-curve. Differences between
Area-under-the-Curve between strata (p<0.05) indicated an association between the vari-
able and sensitivity—specificity of the breath test. Statistical analysis was performed using
STATA/SE 15.
Results
Of 400 enrolled participants, 73 were excluded due to extra-pulmonary TB, incomplete data,
previous TB, and cancer. Calibration phase involved 182 subjects, and the result was
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validated in 287 subjects. Sensitivity was 85% (95%CI: 75–92%) and 78% (95%CI: 70–
85%), specificity was 55% (95%CI: 44–65%) and 42% (95%CI: 34–50%), in calibration and
validation phases, respectively. Test sensitivity and specificity were lower in men.
Conclusion
The electronic-nose showed modest sensitivity and low specificity among patients with sus-
pected PTB. To improve the sensitivity, a larger calibration group needs to be involved. With
its portable form, it could be used for TB screening in remote rural areas and health care
settings.
Introduction
On 26 September, 2018, the United Nations (UN) had a high-level meeting in the UN head-
quarters in New York on tuberculosis (TB). The discussion focused on accelerating actions to
end TB by 2030 [1]. In 2017, the death toll was still huge–with 1.3 Million death, and an addi-
tional 300 000 among HIV-coinfected, TB leads the causes of death by an infectious disease; in
2017 alone, 10 Million people fell ill with TB [1]. Clearly, new diagnostic tools are needed to
identify individuals in the community–and in health care facilities–that continue to spread
this airborne disease. In many TB high-burden countries, pulmonary tuberculosis (PTB) is
commonly diagnosed by sputum smear microscopic examination [1]. Sputum microscopy is
labor-intensive, and the technique does not differentiate Mycobacterium tuberculosis (MTB)
from non-tuberculosis mycobacteria [2]. Though sputum culture is considered gold standard,
it is problematic in low-resource settings, because it is expensive, time-consuming, and vulner-
able to technical failure [3]. Nucleic acid amplification techniques such as Xpert MTB/ RIF
allows for fast identification of MTB [4], but costs remain challenging; it still requires sputum
sampling and is neither portable nor fit for point-of-care in remote rural areas with unstable
electricity supply. For all of the above-mentioned sputum-based tests, appropriate sputum
specimens are required. Meanwhile, not all patients with suspected TB were able to collect an
adequate and good quality sputum sample. Chest radiography (CXR), a non-sputum-based
test that is usually used, lacks specificity [3].
There is an increasing evidence that analysis of exhaled breath using electronic nose (e-
nose) could be used as a novel diagnostic technique [5–9]. An e-nose is a machine that can
detect and differentiate odours from any biological materials, such as breath, urine, or faeces,
with a sensor array. This array consists of non-specific sensors. An odour stimulates the sensor
array to produce a specific fingerprint. Patterns or fingerprints from known odours are used to
build a model and train a pattern recognition system, thus unknown odours can be classified
based on this model [10]. E-nose has been used for diagnosis of various diseases, i.e. asthma
[5], Chronic Obstructive Pulmonary Disease (COPD) [5,6], urinary tract infection [7], lung
cancer [8], and brain cancer [9]. A prototype of an e-nose to diagnose PTB was used by Bruins
et al. in Bangladesh [11]. They found sensitivity of 93.5% and a specificity of 85.3% to differen-
tiate PTB patients from healthy controls, and a sensitivity of 76.5% and specificity of 87.2%
when differentiating PTB patients from other subjects (non-PTB patients and healthy subjects)
[11]. However, this e-nose prototype used separate bags to collect exhaled breath that might
introduce errors due to interaction between the Volatile Organic Compounds (VOCs) with
the bags materials [12]. A newer device that is portable, use rechargeable battery, and does not
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use separate bags (Aeonose) was tested in Paraguay, and showed high sensitivity (88%) and
specificity (92%) to differentiate PTB patients from asthma/COPD and healthy subjects [12].
No previous studies have investigated the potential of the e-nose (Aeonose) device to diag-
nose PTB among patients presenting with signs and symptoms suggesting PTB, while this
would typically provide the added value of such test. We therefore investigated the diagnostic
potential of Aeonose to identify PTB among patients with suspected PTB. Our secondary
objective was to investigate factors that associated with the sensitivity and specificity of the
breath test. The study was conducted in Indonesia, a lower-middle-income country with a
population of 264 million, being the third highest TB-burdened country in the world [1].
Many patients live in remote rural areas with difficult access to health care facilities and




In this diagnostic cross-sectional study, we enrolled a cohort of patients with suspected TB and
healthy controls. We conducted breath tests, and followed study participants over time to con-
firm correct diagnosis. Patients with suspected TB were recruited consecutively from the pub-
lic lung clinics in Yogyakarta and Dr. Sardjito Hospital, Yogyakarta, Indonesia between
October 2013 and December 2015. Healthy controls were recruited from neighboring area of
subjects who were diagnosed with PTB. Subjects were aged�18 years, agreed to participate in
the study, were able to produce sputum (except for healthy controls) and exhaled air samples.
Healthy controls should have no sign nor symptoms of TB. Subjects were excluded if they had
invalid measurements of breath tests, incomplete CXR data, missing sputum specimens
(except for healthy controls), incomplete follow-up, or a previous history of PTB or extra-pul-
monary TB. Subjects were further excluded from the analysis if they had cancer, because can-
cer has been known to interfere with the breath prints [8,9]. All subjects followed the same
diagnostic work-up.
The study protocol followed the guidelines of the Helsinki Declaration of 2013, was
approved by the institutional review board at the Faculty of Medicine, Universitas Gadjah
Mada, Yogyakarta, Indonesia (KE/FK/859/EC), and registered at clinicaltrials.gov
(NCT02219945). Written informed consent was obtained from each subject before enrollment
in the study.
Test methods
The Aeonose (eNose BV, Zutphen, The Netherlands) is an e-nose device combining 3 different
metal-oxide sensors (Applied Sensors Gmbh) and a pre-concentrator (Fig 1). A small pump
inside the Aeonose ensures that a constant flow of exhaled air passes the three sensor surfaces
and a Tenax tube, which enables detecting low concentrations and high boiling Volatile
Organic Compounds (VOCs). A 32-step sinusoidal modulation of the sensor surface with tem-
perature between 260–340˚C is used to measure the volatile molecular pattern in exhaled air in
terms of sensor’s conductivity values. Study participants breathed normally through the Aeo-
nose via a disposable mouthpiece for 5 min. This mouthpiece contains a High Efficiency Par-
ticulate Air-filter protecting the Aeonose from getting contaminated by bacteria and viruses;
and a valve and carbon filter that prevents interference by Volatile Organic Compounds
(VOCs) in the environment that could distort the measurement. A nose clamp was used to
prevent non-filtered air from entering the device and to ensure that the total exhaled volume
during tidal breathing passed through the device. After measuring the breath, the sensors are
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regenerated for 10 minutes. The breath data were downloaded into a laptop, and uploaded
onto the website of eNose for analysis.
As part of routine examination, all patients were characterized by clinical symptoms (per-
sistent cough, unintentional�5% weight loss, and night sweats), three sputum smear micro-
scopic examinations, and CXR. For research purposes, we added sputum culture, HIV testing,
and follow-up for 1.5 years after diagnosis. Patients whose culture results disagreed with the
initial clinical diagnosis (i.e. culture was positive for MTB, but the clinical diagnosis was non-
PTB, or culture was negative despite a clinical diagnosis of PTB) were followed up for 2.5
years. Results of PTB routine examination were available to those seeing the patients during
follow-up, but not to the laboratory personnel who processed the culture.
All these data formed a Composite Reference Standard (CRS) [14,15] that classified partici-
pants into four categories: active PTB (subjects who scored PTB by all tests), no PTB or
Healthy controls (subjects who scored no-PTB by all tests), and patients whose test results clas-
sified in between these two extreme groups (Table 1). Follow-up as a part of a CRS has been
used successfully in different settings [15–18]. Culture though gold standard for TB but single
spot sputum culture is challenging; low quality of sputum samples and laboratory errors may
jeopardize both sensitivity and specificity. The CRS that diagnoses TB based on comprehensive
results of clinical symptoms, bacteriological examinations, CXR, and follow-up, could address
these drawbacks of culture [15,19].
Demographic data, smoking history, co-morbidities (Type II diabetes mellitus, HIV,
COPD, asthma), presence of flu-like illness, presence of psychological stress due to breath test,
Fig 1. The Aeonose.
https://doi.org/10.1371/journal.pone.0217963.g001
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co-medication including antibiotics, and food and beverage intake�8 hours before the test
were recorded.
Sample analysis
Sputum Ziehl-Neelsen microscopy and culture on Lo¨wenstein-Jensen media followed WHO
guidelines [20], in the TB-Microbiology laboratory, Faculty of Medicine Universitas Gadjah
Mada. For research purposes, the CXRs read by the attending physicians were re-read by one
independent physician (TSW–a pulmonologist). In case of disagreement, the conclusion from
the independent reviewer was followed, and the result of this re-reading was used for the CRS.
The breath data were standardized to facilitate measurements between different Aeonose
devices. Temperature control of the sensors was key in order to use multiple metal-oxide sen-
sor eNoses in a single study and later on in validation process; when the sensor temperature
was kept within narrow limits, sensors with similar material properties showed similar
response to VOC’s. When the sensors age, the signal may decrease due to a reduced number of
active sites at the sensor surface. Differences between sensors because of aging were removed
in data pre-processing by rescaling the distribution of values (subtracting the mean value or
centering the data) so that the mean of observed values is 0 and the standard deviation is 1
[21].
The data were compressed with a TUCKER3-solution, and analyzed using an artificial neu-
ral network, thus VOC-samples from individuals could be classified as ‘sick’ or ‘healthy’.
Results were obtained for different scaling preprocessing methods, seven sensor combinations
and several artificial neural network-topologies resulting in multiple models representing the
measurement data. The models were presented in Receiver Operating Characteristic (ROC)-
curves indicating trade-offs for sensitivity and specificity of breath test in diagnosing PTB, and
the best Area Under the Curve (AUC) was selected. Leave-10%-Out cross validation was
applied.
We started with a calibration phase to build a breath model, involving participants in
“Active PTB”, “no PTB”, and “Healthy control” groups. The e-nose can only classify unknown
patients correctly if the patient characteristics (indication, social status, geographical area) are
similar to the ones in the calibration set to have fair classification. Therefore, when collecting
the breath samples, we kept participants from the “Probably active PTB” and “Probably no
PTB” groups blinded for validation purposes. In this validation phase, the blinded breath sam-
ples were classified based on the model generated in the calibration phase [22].
Table 1. Composite reference standard used in the study [14–18].
Type of test Active
PTB
Probably active PTB Probably no PTB No PTB or
Healthy
controls
At least 2 out of 3 clinical
symptoms suggest PTB
Yes (a) 4 tests suggest TB including sputum smear; OR (b) 3
tests suggest TB, including culture and/or follow-up; OR
(c) 2 tests (culture AND follow-up) suggest TB
(a) 1 test suggest TB; OR (b) 2 tests suggest TB,
except culture and/or follow-up; OR (c) 3 tests












Follow-up suggests PTB Yes No
PTB: pulmonary tuberculosis
https://doi.org/10.1371/journal.pone.0217963.t001
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We calculated the sensitivity, specificity, and positive and negative predictive values (PPV
and NPV) of the breath test using the CRS as the reference standard. To examine the influence
of age, participants were divided into 2 groups, based on the median age. In each variable, one
stratum’s Receiver Operating Characteristic (ROC)-curve indicating sensitivity and specificity
of breath test was compared with another stratum’s ROC-curve. A significant difference of an
AUC between strata (p<0.05) indicated an association between the variable and sensitivity—
specificity of the breath test. Statistical analysis was performed using STATA/SE 15 (License:
University of Groningen).
To detect a difference of 15% between the CRS and the breath test with a desired sensitivity
of 90%, and assuming a prevalence of TB of 36% among the study subjects based on previous
data in the lung clinics (unpublished data), with an α error of 0.05 and a power of 90%, the
number of patients with suspected PTB needed for the study was 300 [23]. We followed the
STARD guidelines for reporting as appropriate.
Results
We included 360 consecutive patients with suspected PTB and 40 healthy controls; 73 study
participants were excluded for various reasons, resulting in a total of 327 study participants
(Fig 2). Table 2 shows that median age of study participants in calibration and validation phase
was 40 (range: 18–85) and 46 (range: 18–85) years old, respectively. Diagnoses for patients
who turned out to have no PTB included asthma, pneumonia, bronchiectasis, chronic bron-
chitis, COPD, Obstructive Syndrome Post TB, lung fibrosis, lung abscess, empyema, and poly-
cystic lung disease.
Table 3 shows that in the calibration phase, the number of breath test results with false pre-
diction of the presence of PTB was 57, while number of true breath test results was 125. Fig 3
shows the ROC curve of best model in sensitivity and specificity of breath test in the calibra-
tion phase; sensitivity was 85% (95%CI = 75–92) and specificity was 55% (95%CI = 44–65)
(Table 4). ROC curves from each strata in various variables are shown in Fig 4, while Table 5
shows that the test was significantly more sensitive and specific for women than for men. Fig 5
shows the ROC curve of best model in sensitivity and specificity of breath test in the validation
phase; sensitivity was 78% (95%CI = 70–85%), specificity was 42% (95%CI = 34–50%), PPV
was 52% (95%CI = 48–56%), and NPV was 71% (95%CI = 62–78%) (Table 6).
There were no adverse events (e.g., breathless, infection, or bleeding) associated with the
study intervention.
Discussion
This is the first study testing the e-nose (Aeonose) to diagnose PTB among patients with sus-
pected PTB. The study in Bangladesh used a prototype of the e-nose (participants exhaled into
a bag, then the bag content was examined using a laboratory version of the e-nose), and with
smaller sample size [11]. Other studies with e-nose devices did not diagnose PTB among
patients with suspected PTB [12,24,25]. The sensitivity in our study was modest, while specific-
ity was low.
We evaluated several factors that may associate with the breath prints, i.e. physiological fac-
tors (age, sex, food, beverages), pathological and disease-related conditions (smoking, comor-
bidities, medication), and sampling-related issues (bias with VOCs in the environment) [26].
A previous study revealed that older age altered breath prints in patients with lung cancer [27].
Patients with high body mass index (BMI) had more false-positive test results compared to
patients with normal or low BMI [12], males had higher level of isoprene compared to females
[28], consuming poultry meat, plant oil, and some beverages could be differentiated by an e-
E-nose in diagnosing pulmonary TB among TB suspects
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Fig 2. Flow-chart of study participants.
https://doi.org/10.1371/journal.pone.0217963.g002
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nose, and smoking increased the levels of benzene and pentane [29–34]. In our study, we
found that the sensitivity and specificity of the breath test were lower in men compared to
women. The cause was not entirely clear; higher level of isoprene in men might reflect oxida-
tive stress that can influence the progression of disease [35]. It could be also that a difference in
smoking, eating, or other habits influences this difference. To prevent interference by VOCs in
the environment such as ethanol and isopropanol [36], the Aeonose was equipped with a valve
and carbon filter, thus the breath prints were not biased by the room air.
The Aeonose was developed by using arrays based on less (or non-) specific sensors com-
bined with smart data compression and pattern recognition, namely metal-oxide sensors. This
pattern recognition technique matches measured ‘patterns’ to previously ‘seen’ patterns.
Therefore, a substance, or mixtures of substances, can only be recognized after a calibration
phase: in order to match a pattern, it must be known beforehand (i.e., ‘seen’ before). In exhaled
Table 2. Characteristics of study participants in each category.
Characteristic




No PTB (n = 57)
Validation phase Active PTB
(n = 85)




Sex male, % 60.0 69.4 56.1 60.5 60.8
Age, years median (min-max) 35 (18–66) 38 (19–80) 47 (22–85) 41 (18–77) 52 (19–80)
Body mass index, kg/m2 median (min-
max)
23.4 (17.2–32.9) 18.1 (14.0–
27.9)
20. 9 (13.8–36.7) 18.2 (11.3–25.0) 19.9 (11.9–30.1)
HIV infection, n (%) 0 (0.0) 1 (1.2) 0 (0.0) 3 (7.0) 1 (1.0)
Type II diabetes mellitus, n (%) 1 (2.5) 10 (11.8) 3 (5.3) 6 (14) 4 (3.9)
PTB: pulmonary tuberculosis, HIV: human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0217963.t002


















Cough>2 weeks (yes/no), n 0/40 83/2 52/5 42/1 102/0
Unintentional�5% weight loss (yes/no), n 0/40 76/9 1/56 35/8 73/29
Night sweats (yes/no), n 0/40 66/19 2/55 25/18 47/55
Sputum examination
Three sputum smear microscopy tests (negative/ positive/
unknown), n
9/0/31 2/83/0 57/0/0 20/23/0 101/1/0
Sputum culture (negative for PTB/positive for PTB/
unknown), n
9/0/31 0/85/0 57/0/0 33/10/0 97/5/0
Chest radiography (not suggestive for PTB/ suggestive for
PTB), n
40/0 0/85 57/0 5/38 73/29
Follow up (not suggesting PTB/ suggesting PTB), n 40/0 0/85 57/0 1/42 102/0
Breath test results (negative/ positive PTB), n 27/13 13/72 26/31 15/28 41/61
PTB: pulmonary tuberculosis
https://doi.org/10.1371/journal.pone.0217963.t003
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breath, several thousands of VOCs can be recognized. When comparing breath patterns
between people suffering from a certain disease and controls, the Aeonose can be taught to dif-
ferentiate and identify the diseased population. This technique provides less detailed informa-
tion compared to chemical-analytic methods or spectroscopic techniques that work by
detecting VOC markers, although classification of the results remains possible. Philips et al.
found that naphthalene, 1-methyl- and cyclohexane, 1,4-dimethyl- were breath VOC markers
that are sensitive and specific for pulmonary TB [37]. Detecting these markers might lead to
Fig 3. ROC curve of best model in diagnostic sensitivity and specificity of breath test, calibration phase. ROC = Receiver Operating Characteristic.
https://doi.org/10.1371/journal.pone.0217963.g003










Positive breath test 72 44 85 (75–92) 55 (44–65) 82 (75–88)
Negative breath test 13 53
PTB: pulmonary tuberculosis, AUC: area under the curve, CI: confidence interval
agenerated from the real value
https://doi.org/10.1371/journal.pone.0217963.t004
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better sensitivity and specificity. However, the insights of what VOC-markers should be picked
are changing over time, resulting in other combinations of VOC-markers. The chemical-ana-
lytic methods or spectroscopic techniques also have several drawbacks: they need well-condi-
tioned environment, especially when concentration differences of biomarkers are to be
recorded; they cannot be used as a point-of-care diagnostic test due to their large size; and
well-trained staff are needed to operate the devices.
The Aeonose provides non-invasive diagnosis support in minutes, is easy-to-use, without
the need for robust training. In a new release of the Aeonose, an iPad is used, and the test result
is provided within seconds. Charging of the device only needs a low electricity usage, as with
charging of mobile phones. It is portable, thus suitable as a screening tool. Therefore, it might
help to prevent TB transmission, also serve well in health care settings, with further advanced
and more expensive testing for individuals picked up by the breath test.
We excluded non-TB patients with a previous history of pulmonary and extra pulmonary
TB because several breath profiles of non-TB patients with a previous history of TB showed
similar breath profiles with TB. Scares and persistent or dead MTB in the lung could be mimic-
ries of TB [38]. We also excluded patients with cancer because cancer interferes with the breath
test [8,9]. We were aware of the fact that in daily practices it is difficult to separate patients
Fig 4. ROC curve of best model in diagnostic sensitivity and specificity of breath test, validation phase. ROC = Receiver Operating Characteristic.
https://doi.org/10.1371/journal.pone.0217963.g004
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Table 5. Performance of breath test results in the calibration phase, stratified by various variables.







Positive breath test 47 27 64 86 76
Negative breath test 12 29 (51–76) (74–94) (67–85)
Female
Positive breath test 25 17 81 88 93
Negative breath test 1 24 (61–93) (74–96) (87–99)
Age, n 0.9683
>40 years
Positive breath test 33 20 73 90 82
Negative breath test 8 28 (57–86) (77–97) (72–91)
�40 years
Positive breath test 39 24 66 84 81
Negative breath test 5 25 (50–80) (70–93) (72–90)
Body Mass Index (BMI), n b
Overweight (BMI �25 kg/m2)
Positive breath test 1 9 100 95 100
Negative breath test 0 13 (2.5–100) (77–100) (100–100)
Underweight or Normal (BMI<18.5 kg/m2 or 18.5-<25 kg/m2)
Positive breath test 71 35 69 84 80
Negative breath test 13 40 (58–79) (74–91) (73–87)
Type II diabetes mellitus, n 0.1771
Presence of Type II DM (+)
Positive breath test 6 2 50 75 63
Negative breath test 4 2 (19–81) (19–99) (34–91)
Presence of Type II DM (-)
Positive breath test 66 42 72 87 84
Negative breath test 9 51 (60–82) (79–93) (77–90)
HIV infection, n b
Presence of HIV infection (+)
Positive breath test 1 0 100 N.A. N.A.
Negative breath test 0 0 (2.5–100)
Presence of HIV infection (-)
Positive breath test 71 44 69 87 81
Negative breath test 13 53 (58–79) (78–93) (75–88)
Presence of COPD, n b
Presence of COPD (+)
Positive breath test 0 1 N.A. 0 N.A.
Negative breath test 0 0 (0–98)
Presence of COPD (-)
Positive breath test 72 43 69 88 82
Negative breath test 13 53 (58–79) (79–93) (76–89)
(Continued)
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Table 5. (Continued)





Presence of asthma, n b
Presence of asthma (+)
Positive breath test 1 0 0 N.A. N.A.
Negative breath test 0 0 (0–98)
Presence of asthma (-)
Positive breath test 71 44 70 87 82
Negative breath test 13 53 (59–80) (78–93) (75–88)
Use of antibiotics, n 0.6794
Antibiotic use (+)
Positive breath test 7 2 75 75 86
Negative breath test 1 2 (35–97) (19–99) (64–100)
Antibiotic use (-)
Positive breath test 65 42 69 87 81
Negative breath test 12 51 (57–79) (79–93) (74–88)
Presence of flu, n b
Presence of flu (+)
Positive breath test 1 3 100 100 100
Negative breath test 0 4 (3–100) (59–100) (100–100)
Presence of flu (-)
Positive breath test 71 41 69 86 81
Negative breath test 13 49 (58–79) (77–92) (74–88)
Presence of psychological stress due to breath test, n b
Presence of stress (+)
Positive breath test 0 0 NA. 100 N.A.
Negative breath test 0 2 (16–100)
Presence of stress (-)
Positive breath test 72 44 69 86 81
Negative breath test 13 51 (58–79) (78–93) (75–88)
Prior food intake, n 0.4059
Prior food intake (+)
Positive breath test 61 34 70 90 83
Negative breath test 12 46 (58–80) (81–96) (77–90)
Prior food intake (-)
Positive breath test 11 10 67 71 75
Negative breath test 1 7 (35–90) (44–90) (56–93)
Prior beverage intake, n 0.2849
Prior beverage intake (+)
Positive breath test 41 23 60 91 79
Negative breath test 12 30 (46–74) (79–97) (70–88)
Prior beverage intake (-)
Positive breath test 31 21 84 82 85
Negative breath test 1 23 (67–95) (67–92) (77–94)
(Continued)
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with lung cancer from patients with TB as patients with lung cancer are likely to have a clinical
presentation that mimics TB, however, the number of patients with cancer was also too low (5
patients) precluding a separate group data analysis. The diagnostic potential if any of the Aeo-
nose for these patients was not addressed in this study.
This study revealed lower sensitivity and specificity in comparison to the study from Ban-
gladesh [11] and Paraguay [12], which is likely caused by the difference in the study popula-
tions. In our study, the non-PTB patients were patients with suspected PTB, thus it captured
the infectious or non-infectious lung diseases, and acute or chronic lung diseases. In the study
from Paraguay, non-TB subjects comprised asthma and COPD patients (patients with stable
chronic lung disease), who usually have quite distinct clinical presentations than TB patients.
The diversity of participants in our study is larger than in the Bangladesh and Paraguay stud-
ies, thus probably more participants are needed in the calibration phase to get comparable per-
formance between calibration and validation phase. When an artificial neural network should
predict a breath profile it hasn’t ‘seen’ during the calibration phase, a false prediction is more
likely. A larger calibration group would improve the blind predictions.
Using the current sensitivity, 22% of patients would be missed, which is higher than screen-
ing by CXR which has 87% sensitivity [39]. Nevertheless, the breath test has advantages of
being portable, easy-to-use, and without radiation exposure making it suitable as a repeatable
screening test. Notably, approximately 30% of active tuberculosis cases are currently not
detected by the national health care system [40]; as calculated within the last TB incidence [1],
this test will improve case finding by as many as 67,360 cases. Furthermore, this test has higher
sensitivity than symptoms screening, that only had 63% sensitivity from our data, or 70% sen-
sitivity from a previous systematic review [39].
The strength of this study is that cohorts of patients and controls were recruited as a calibra-
tion and validation group, with the potential to confirm the correct classification. This study
also has some limitations. It was performed in Yogyakarta province alone, however the
Table 5. (Continued)





Smoking before test, n 0.2082
Smoking <8 hours ago
Positive breath test 2 1 20 80 56
Negative breath test 3 4 (1–72) (28–99) (17–95)
Smoking�8 hours ago or never
Positive breath test 70 43 73 87 84
Negative breath test 10 49 (61–82) (78–93) (78–90)
Alcohol consumption before test, n b
Alcohol consumption <8 h ago
Positive breath test 0 0 N.A. N.A. N.A.
Negative breath test 0 0
Alcohol consumption�8 h ago or never
Positive breath test 72 44 69 87 82
Negative breath test 13 53 (58–79) (78–93) (75–88)
PTB: pulmonary tuberculosis, AUC: area under the curve, CI: confidence interval
agenerated from the real value
bcannot be compared because one AUC is 100% or one AUC cannot be computed.
https://doi.org/10.1371/journal.pone.0217963.t005
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organization of lung clinics in Yogyakarta is typical and representative for Indonesia. We used
Lo¨wenstein-Jensen culture, which has lower sensitivity compared to liquid culture, and we
used mostly only one specimen for culture. Nevertheless, Lo¨wenstein-Jensen culture may have
higher specificity due to lower contamination rates [41–43]. As mentioned above, the e-nose
Fig 5. ROC curves of sensitivity and specificity of breath test in calibration phase, stratified by variables. ROC = Receiver Operating Characteristic,
AUC = Area Under the Curve. ROC curves of best model in diagnostic sensitivity and specificity of breath test stratified by presence of HIV infection, COPD,
asthma, or physiological stress could not be generated due to missing value of sensitivity or specificity in one strata.
https://doi.org/10.1371/journal.pone.0217963.g005























(62–78)Negative breath test 28 67
PTB: pulmonary tuberculosis, AUC: area under the curve, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value
agenerated from the real value
https://doi.org/10.1371/journal.pone.0217963.t006
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provides less detailed information compared to chemical-analytic methods or spectroscopic
techniques. To improve the sensitivity and specificity of the device, a larger calibration group
needs to be involved. Once the VOC-markers for TB are adequately determined, the use of
highly selective sensors that target these VOC-markers may also add the sensitivity and
specificity.
In conclusion, the Aeonose had modest sensitivity and low specificity to diagnose TB
among patients with suspected TB in Indonesia. With its portable form, it could be used for
TB screening in remote rural areas with difficult access to health care facilities, as well as a
screening tool in health care settings to reduce the risk of nosocomial TB transmission.
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